Indication
Ciprofloxacin is used in adults for the treatment of urinary tract infections, lower respiratory tract infections and skin & skin structure infections, bone and joint infections, and G.I. infections (enteric fever, infectious diarrhea) caused by susceptible gram-negative and gram-positive aerobic bacteria. It is also used for the treatment of uncomplicated urethral gonorrhea caused by penicillinase and non-penicillinase-producing Neisseria gonorrhoeae.
Dosage & Administration
Inflections |
Type of Severity |
Unit Dose |
Frequency |
Duration |
Unit Tract |
Mild/Moderate |
Severe/Complicated |
Acute Systitis |
|
|
|
7-14 days |
7-14 days |
3 days |
|
Chronic Bacterial
Prostatis |
Mild/Moderate |
500 mg |
b.i.d |
28 days |
Lower Respiratory
Tract |
Mild/Moderate |
Severe/Complicated |
|
|
|
|
Acute Sinusitis |
Mild/Moderate |
500 mg |
b.i.d |
10 days |
Skin & Skin
Structure |
Mild/Moderate |
Severe/Complicated |
|
|
|
|
Bone and Joint |
Mild/Moderate |
Severe/Complicated |
|
|
|
|
Intra-Abdominal |
Complicated |
500 mg |
b.i.d |
7-14 days |
Infectious Diarrhea |
Mild/Moderate/Severe |
500 mg |
b.i.d |
5-7 days |
Typhoid Fever |
Mild/Moderate |
500 mg |
b.i.d |
10 days |
UrethralCervical
Gonococcal
Infections |
Ubncomplicated |
250 mg |
Single dose |
Single dose |
Inhalational
Anthrax
( Post-exposure ) |
|
500 mg |
15 mg/kg/dose;
not to exceed
500 mg/dose |
|
|
|
Generally Ciprofloxacin should be continued for at least 2 days after the signs and symptoms have disappeared, except for inhalational anthrax (post-exposure). Patients whose therapy is started with Ciprofloxacin I.V. may be switched to Ciprofloxacin tablets or suspension when clinically indicated at the discretion of the physician.
Pediatric Patient & Adolescents (1 to 17 years of age)
Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli.
Inflections |
Rule of Administration |
Dose (mg/kg) |
Frequency |
Duration |
Complicated
Urinary Tract or
Pyelonephritis |
|
10-20 mg/kg
(Max. 750 mg/dose; not
to be exceeded even in
patients weighing >51 kg) |
6-10 mg/kg
(Max. 400 mg/dose; not
to be exceeded even in
patients weighing >51 kg) |
|
|
10-12 days |
Inhalational
Anthrax
(Post-exposure) |
|
15 mg/kg
(Max. 500 mg/dose) |
10 mg/kg
(Max. 400 mg/dose) |
|
|
60 days |
Precautions
Ciprofloxacin should be used with caution in patients with a history of convulsive disorders. Crystalluria related to the use of Ciprofloxacin has been observed very rarely. Patients receiving Ciprofloxacin should be well hydrated and excessive alkalinity of the urine should be avoided. Use in Pregnancy: As with other quinolones, Ciprofloxacin has been shown to cause arthropathy in immature animals and therefore its use during pregnancy is not recommended. Use in Lactation: Studies in rats have indicated that Ciprofloxacin is secreted in milk; administration to nursing mothers is thus not recommended.
Direction for Reconstitution
CivoxTM Suspension: The small bottle contains the pellets; the large bottle contains the diluent. Pour the pellets (from small bottle) completely into the large bottle of diluent. Do not add water to the suspension. Close the bottle tightly & shake vigorously until it is properly mixed. The suspension is ready for use. Shake the bottle well before each use.